- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04985903
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
April 20, 2026 updated by: Duke University
The investigators propose to conduct a combined intervention that pairs SMS smoking cessation messages for patients with individualized training for OB clinicians to improve quit rates among pregnant smoking.
The aim is to determine the effect of the intervention versus control on smoking cessation outcomes on patient smoking cessation.
The investigators will recruit patients at their first OB visit who report smoking at Duke and Pitt.
Patients in both the control and intervention arm will receive smoking cessation support messages throughout their pregnancy.
OB clinicians in the intervention arm will receive tailored smoking cessation counseling training.
Clinicians in both arms will receive a one-time 5 A lecture.
The investigators will analyze smoking cessation outcomes and audio recordings.
This is a minimal risk study.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The investigators propose a two-arm cluster randomized controlled design, in which the unit of randomization is the OB clinician.
70 OB clinicians will be randomly assigned to either the intervention or control condition.
Although the unit of randomization is the clinician, the unit of evaluation is the patient: range of 6-13 patients per clinician (1-3 Pre-intervention and 5-10 Post-intervention) who receive prenatal care from enrolled OB clinicians at Duke and UPitt.
The investigators will collect 3 Pre-Intervention audio-recorded initial OB visit encounters to assess pre-intervention levels of clinician communication skills and also to tailor the clinician training program.
After the Pre-Intervention Phase, the investigators will randomize OB clinicians to either the intervention or control arm (see details of cluster randomization below).
All OB clinicians will attend a lecture about the consequences of smoking during pregnancy and the elements of the 5 A's.
Only OB clinicians randomized to the intervention arm will receive an individually-tailored, user-friendly, web-based program that teaches the 5 A's.
In the Post-Intervention Phase, the investigators will assess the effect of the communication program by audio recording initial OB visits for between 5-10 pregnant women who smoke for each OB clinician in both arms (n=542 total).
The investigators will provide all patients the SMS text-delivered intervention.
Additionally, the investigators will survey these patients before their visit, immediately after their visit, at the end-of-pregnancy, and 6-weeks postpartum.
Due to anticipated study attrition, the investigators will recruit up 80 clinicians and 700 patients at both sites until the investigators reach a complete data set for our desired sample size.
Biochemically validated smoking cessation at end-of-pregnancy is the primary outcome (Aim 1).
To assess Aim 2, investigators will code for clinician use of the 5 A's in the audio-recorded encounters and analyze patient perceptions of the communication from post-encounter data and the post-study survey for clinicians.
To assess Aim 3, investigators will collect smoking status at 6 weeks postpartum.
Study Type
Interventional
Enrollment (Estimated)
840
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27704
- Durham OB
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- ≥18 years old
- Receiving prenatal care from an enrolled OB clinician
- Self-report smoking tobacco at their first OB visit
- Access to a cell phone with texting capabilities
Exclusion Criteria:
- Unable to speak and read English
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
Clinicians in the intervention arm will receive a tailored communication training on smoking cessation skills and a general lecture on smoking cessation.
|
The focus of the communication program is to help clinicians increase their use of the 5 A's by improving knowledge, self-efficacy, outcome expectations, and communication skills.
Training modules include didactic information with video clips of sample conversations showing specific communication skills, feedback on clinician's usage of the 5A's, and audio clips from their Pre-Intervention recorded conversations.
a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
|
|
Active Comparator: Control
Clinicians in the control arm will be asked to attend a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
|
a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Patients in the Post-Intervention Phase With Validated Cessation
Time Frame: End-of-pregnancy, up to 45 minutes
|
Biochemically validated (urine cotinine) 7-day point prevalent as defined by urine cotinine levels below 50ng/ML.
|
End-of-pregnancy, up to 45 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of A's performed in the Post-Intervention Phase for each Clinician
Time Frame: Post-intervention recordings (all recording will happen prior to giving birth), up to 12 weeks
|
Obtained by coding 11 recordings of patient encounters in the Post-Intervention Phase.
We will follow a codebook to assess the number of A's performed in the Post-Intervention visits for each clinician.
Coders will also assess whether each Advice segment is clear, strong, or personalized.
We will assign advice a score of 0-3 with a score of 3 indicating highest quality of advice.
|
Post-intervention recordings (all recording will happen prior to giving birth), up to 12 weeks
|
|
Mean rated autonomy support for each Post-intervention patient
Time Frame: Baseline, up to 15 minutes
|
6-item Health care climate questionnaire
|
Baseline, up to 15 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kathryn I Pollak, PhD, Duke University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 25, 2022
Primary Completion (Estimated)
May 31, 2026
Study Completion (Estimated)
May 31, 2026
Study Registration Dates
First Submitted
July 22, 2021
First Submitted That Met QC Criteria
July 22, 2021
First Posted (Actual)
August 2, 2021
Study Record Updates
Last Update Posted (Actual)
April 22, 2026
Last Update Submitted That Met QC Criteria
April 20, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00106131
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
National University of SingaporeRecruitingSmoking &Amp; Tobacco CessationSingapore
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedSmoking &Amp; Tobacco CessationUnited States
-
Sultan Qaboos UniversityCompletedSmoking Cessation | Tobacco Use Cessation | Smoking PreventionOman
-
The University of Hong KongCompletedSmoking Cessation Counseling Ability | Smoking Cessation Counseling PracticeHong Kong
Clinical Trials on Clinician Communication Intervention
-
University of RochesterNational Cancer Institute (NCI)Completed
-
Mayo ClinicModernaTX, Inc.CompletedInfluenza Vaccine | COVID-19 ImmunisationUnited States
-
University of WashingtonUniversity of NairobiCompleted
-
University of WashingtonNational Institute on Aging (NIA)CompletedLiver Cirrhosis | Lung Neoplasms | Neoplasm Metastasis | Pulmonary Disease, Chronic Obstructive | Dementia | Kidney Failure, Chronic | Chronic Disease | Peripheral Vascular Disease | Lung Diseases, Interstitial | Heart Failure, Congestive | Diabetes With End Organ InjuryUnited States
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Duke UniversityCompleted
-
University of WashingtonNational Institute on Aging (NIA)CompletedLiver Cirrhosis | Neoplasm Metastasis | Pulmonary Disease, Chronic Obstructive | Dementia | Kidney Failure, Chronic | Chronic Disease | Peripheral Vascular Disease | Lung Diseases, Interstitial | Lung Neoplasm | Heart Failure,Congestive | Diabetes With End Organ InjuryUnited States
-
Massachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingType 2 Myocardial InfarctionUnited States
-
Ontario Shores Centre for Mental Health SciencesUS Department of Veterans AffairsCompletedPostTraumatic Stress Disorder
-
Centers for Disease Control and PreventionUniversity of GeorgiaCompletedHIV Infections | Sexually Transmitted Diseases | PregnancyUnited States